Rituximab in Steroid-Dependent Podocytopathies
Rituximab (RTX) seems to be an effective treatment alternative in primary forms of MCD and FSGS, particularly in cases of steroid dependence and frequent relapses. Our findings support the use of RTX for a steroid-free remission in podocytopathies and suggest that maintenance RTX is well-tolerated and associated with prolonged remission. Further studies are needed to confirm its efficacy and safety and establish the optimal induction and maintenance RTX regimen in steroid-dependent podocytopathies.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Rituximab in Steroid-Dependent Podocytopathies ; volume:4 ; number:1 ; year:2024 ; pages:129-136 ; extent:8
Glomerular Diseases ; 4, Heft 1 (2024), 129-136 (gesamt 8)
- Creator
-
Costa, Cláudia
Antunes, Amélia
Oliveira, João
Pereira, Marta
Godinho, Iolanda
Fernandes, Paulo
Jorge, Sofia
Lopes, José António
Gameiro, Joana
- DOI
-
10.1159/000539922
- URN
-
urn:nbn:de:101:1-2412260109196.029145747586
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Costa, Cláudia
- Antunes, Amélia
- Oliveira, João
- Pereira, Marta
- Godinho, Iolanda
- Fernandes, Paulo
- Jorge, Sofia
- Lopes, José António
- Gameiro, Joana